Objective: To measure the association between the class of antidepressant (AD) used according to trimester of exposure during pregnancy and infants born small for gestational age (SGA).
T here is considerable uncertainty surrounding the safety of AD use during pregnancy. Indeed, concerns have been put forward regarding their impact on prematurity and birth weight. Most studies that have investigated AD use during pregnancy have considered prematurity (a gestational age of less than 37 weeks) and LBW (less than 2500 grams) as 2 distinct outcomes. Most of these studies 1, 2 have suggested that AD use during pregnancy increased the risk of preterm birth and LBW. However, an infant born preterm may have a normal weight for his or her gestational age, whereas one born at term may have an abnormal weight for the gestational age. These 2 scenarios have specific clinical implications. For these reasons, using outcomes such as gestational age and birth weight separately do not allow to evaluate the real impact of AD use during pregnancy on infants. Further, there is no consensus as to which trimester of pregnancy or which AD class increases the risk of prematurity and LBW. 2 -4 SGA is a sex-specific measure that combines both gestational age and birth weight. An infant born SGA is one whose birth weight is below the 10th percentile.' SGA infants have been shown to suffer from growth restrictions, and are thus at an increased risk ofdeath compared with non-SGA infants." Further, those who survive may suffer from permanent deficits in growth and neurocognitive development in later childhood," and be at an increased risk for chronic diseases in adulthood. 8 Only a few studies have investigated the association between AD use during pregnancy and infants born SGA. Moreover, these studies had small sample sizes,9,IO did not fully adjust for confounders,lo-l2 or did not have an adequate control group." Indeed, without adjustment on important confounders, a study!' performed on 1243 pregnant women found that AD use during gestation increased the risk of prematurity (P < 0.05) but not LBW or SGA. Based on 450 pregnant women, another study" showed that SSRI or ven1afaxine use during pregnancy did not have a significant effect on birth weight or gestational age. Therefore, the primary objective of our study was to quantify the association between AD class used during pregnancy and infants born SGA, according to trimester of exposure. 
Materials and Methods

Data Sources
We used 3 administrative databases of the province of Quebec: the RAMQ, Med-Echo, and the Fichier des evenernents demographiques du Quebec (birth and death registries) managed by the ISQ. Data extracted from these databases were supplemented with data obtained from a self-administered questionnaire.
The RAMQ database contains information on medical services (diagnoses and procedures) received by all Quebec residents. All diagnoses are classified according to the ICD-9. 13 Although RAMQ covers all Quebec residents for the cost of physician visits, hospitalizations, and procedures, it covers only a portion of residents for the cost of medications. The RAMQ drug plan covers people aged 65 years and older, recipients ofsocial assistance (welfare recipients), and workers and their families (adherents) who do not have access to a private drug insurance program, accounting for about 43% of the overall Quebec population. 14 It is also estimated that 30% of women aged between 15 and 45 years in Quebec are covered by the RAMQ drug plan for their medications. The Med-Echo database is a provincial database which records acute care hospitalization data for all Quebec residents; it also records birth weight and gestational age for deliveries, planned abortions, and miscarriages. The Fichier des evenements demographiques du Quebec (ISQ) provides demographic information on the mother, father, and baby, as well as birth weight and gestational age for live births and stillbirths. The RAMQ, Med-Echo, and ISQ databases have been used in the past for perinatal epidemiologic research. 15 -19 The ISQ database has also been used in epidemiologic studies." Data recorded in the medication database of the RAMQ have been suitably evaluated and found to be comprehensive and valid. 21 ,22 The same was found for medical diagnoses recorded in the Med-Echo database. 23 The linkage between the RAMQ, Med-Echo, and ISQ was done using an encrypted Numero d' Assurance Maladie, which is a unique identifier for all Quebec residents (between RAMQ and Med-Echo), and using mothers' and babies' dates of birth, first names, and family names (between RAMQ and ISQ).
This linkage enabled the creation of the Quebec Pregnancy Registry, which contains data on all pregnancies that occurred in Quebec between January 1, 1998, and December 31, 2002 . This population-based pregnancy registry is composed of women who were aged between 15 and 45 years on the first day of gestation (first day of last menstrual period available in the Med-Echo and ISQ databases). Pregnancies were identified using diagnostic and procedure codes related to the gestational period. All pregnant women in the cohort also had to be insured for their medications by the RAMQ drug plan for at least I year before and during pregnancy.
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Finally, a self-administered questionnaire was developed and mailed to all study cohort members to supplement information on important confounders not present in the Quebec Pregnancy Registry. The questionnaire was developed in French and English. It was also pre-tested in a convenience sample of pregnant women presenting at the obstetrics clinic of CHU Ste-Justine. The variables collected with the questionnaire were pregnancy history, sociodemographic data, and lifestyles.
Our study was approved by the CHU Sainte-Justine Ethics Committee. The linkage between administrative databases and the self-administered questionnaire was approved by the Commission d' Acces it l'Infonnation du Quebec.
Study Population
Within the Quebec Pregnancy Registry, women meeting the following eligibility criteria were included in our study. Women had to have received at least 1 diagnosis ofa psychiatric disorder defined according to the ICD-9 classification (codes: 290 to 319) before pregnancy, have used ADs for at least 30 days in the year prior to pregnancy, and have a pregnancy ending with a live singleton birth. Women with the following diagnoses ofpsychotic or nonpsychotic conditions, or mental retardation (lCD-9 codes: 290 to 295, 297 to 299,302, 303, 305 to 308, 312, and 314 to 319) were excluded because they were unlikely to have been exposed to ADs. Finally, if a woman had more than one pregnancy between 1998 and 2002, the first pregnancy meeting eligibility criteria was considered for analysis.
Study Design
Within the cohort outlined above, a case-eontrol study was performed to determine the association between AD class used and infants born SGA, according to trimester of exposure during pregnancy.
Subjects and Control Subjects
Subjects (SGA) were defined as newborns with a birth weight of less than the 10th percentile for gestational age and sex, according to the population-based Canadian references.l Control subjects were infants with a normal birth weight for their gestational age and sex, having a birth weight ranging between the 10th and 90th percentile. The index date for both subjects and control subjects was the date of delivery.
Exposure Assessment
For each subject and control subject, we assessed exposure to ADs during the first trimester (0 to 14th week of gestational age), second trimester (15 to 26th week of gestational age), and third trimester (27th week or more of gestational age) of pregnancy. AD exposure was defined as having filled at least one AD during the trimesters of interest. This included prescriptions filled before pregnancy or in a previous trimester whose durations overlapped with the trimester of interest.
The Canadian Journal of Psychiatry, Vol 55, No10, October 2010 • AD exposure was also defined according to therapeutic class. The following classes were considered: SSRls, tricyclics, other ADs, and co-exposures (2 classes or more). The following types of ADs were investigated: SSRls (citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline), tricyclies (amitriptyline, clomipramine, desipramine, doxepin, imipramine, nortriptyline, and trimipramine), and other ADs (bupropion, mirtazapine, moclobemide, nefazodone, trazodone, and venlafaxine).
Covariates
For each study woman, analyses were adjusted for the following previously established risk factors for SGA and also for the following variables: in the year prior to pregnancy: the number of different medications used other than ADs, the number of visits to the emergency department or hospitalizations, and the BMI; and on the first day of gestation and during pregnancy: maternal age, race, being a welfare recipient or not, area of residence, parity, income, marital status, maternal weight gain, tobacco, alcohol, and illicit drug use, and finally caffeine intake.
The analyses were also adjusted for maternal markers of comorbidity detected before and during pregnancy: pre-pregnancy and gestational diabetes (lCD-9: 250.0 to 250.9, 271.4, 790.2, 648.0, 648.8, or use of oral hypoglycaemic drugs or insulin), pre-pregnancy and gestational hypertension (ICD-9: 401.0 to 405.9, 362.1,416.0,437.2, 796.2, or use ofantihypertensive drugs), and asthma (lCD-9: 493, with a prescription for an asthma drug).
Severity of the underlying psychiatric condition or nonresponsiveness to the treatment with ADs are important potential confounders. To account for these variables in the analyses, the following proxies were used: the number of days on ADs and the number ofvisits to the psychiatrist in the year prior to pregnancy; the number of different psychiatric disorder diagnoses received prior to and during pregnancy; the use ofan anxiolytic or sedative such as benzodiazepines; and the use of an anticonvulsant such as carbamazepine during pregnancy. Finally, we stratified according to AD dosage used during pregnancy to evaluate the severity of the underlying psychiatric condition. Stratification was made based on dosage distribution.
Statistical Analyses
Descriptive statistics were used to summarize the characteristics of the study population. The association between AD use during pregnancy and the risk ofSGA was assessed using modified Poisson regression models, which provided estimates of RRs and ARRs, along with their respective 95% confidence intervals. RRs are giving the univariate relation between an independent variable, such as AD use, and a dependent variable, which is SGA. ARRs are giving the multivariate relation between an independent variable and SGA, taking into account all other variables that could potentially be risk factors for SGA or explain the observed risk, for example maternal weight or smoking. Analyses were performed in 2 phases. In the first phase, the analyses were performed on the cohort assembled from the linkage of the 3 administrative databases. In the second phase, the analyses were performed on the cohort assembled from the linkage of the 3 administrative databases and using the additional information obtained from the self-administered questionnaire. The hot deck method and an in-house imputation program were used to compute missing values that were present in the questionnaire. All analyses were 2-tailed and P < 0.05 was considered significant. SAS version 8.2 (SAS Institute Inc, Cary, NC) and Stata version 7.0 (StataCorp, College Station, TX) were used to perform analyses.
Sample Size
Using power and sample size calculation software, version 3.0.2, we calculated that 230 to 233 subjects were needed to detect a relative risk of 1.5 with a significance level of 0.05 and a power of 80%. The proportion of control subjects with exposure to AD was assumed to be 40% to 50%, and the correlation coefficient discordance paired subjects was assumed to be 0.224.
Results
Phase 1: Study CohortAnalyses With the 3 Administrative Databases
A total of 152 107 women were included in the Quebec Pregnancy Registry. Among them, 2955 met eligibility criteria, and thus constituted the study population. There were 404 (13.7%) infants born SGA and 249 (8.4%) infants born large for gestational age. The latter group, who were older than the 90th percentile, were not included in the analyses. Hence the study cohort was composed of 2706 mother-infant pairs. Sociodemographic characteristics and health care use variables of these women are presented in Table 1 .
Other AD use during the second trimester of pregnancy was the only AD class that was statistically associated with infants born SGA (ARR = 2.25; 95% CI 1.30 to 3.92) ( Table 2 ). AD co-exposure during the second trimester was also statistically associated with infants born SGA (ARR = 3.48; 95% CI 1.56 to 7.75). The SSRIs-other AD co-exposure during the second trimester of pregnancy was the most frequent co-exposure (n = 23, 69.7%). No statistically significant associations were found between the other classes (SSRIs or tricyclics) used during pregnancy and the risk of infants born SGA ( Table 2 ).
Phase 2: Study CohortAnalyses With Administrative Databases and Self-Administered QuestionnaireData
Among the original cohort defined within administrative databases (n = 2955), 938 (32%) women responded to the self-administered questionnaires, thus providing information on potential additional confounders. This subsample was used 646 for the second phase of our analyses. Sociodemographic characteristics, health care lise variables, and lifestyle of these respondents are presented in Table 1 .
Other AD use during the second trimester of pregnancy was statistically associated with having an infant born SGA (ARR = 2.41; 95% CI 1.07 to 5.43) ( Table 3 ). AD co-exposure during the second trimester was also statistically associated with infants born SGA (ARR = 3.28; 95% CI 1.28 to 8.45) ( Table 3 ). The SSRIs-other ADs co-exposure during the second trimester of pregnancy was the most frequent co-exposure (n = 10/12,83.3%).Hypertension, race, tobacco use, and having at least one mental disorder diagnosis increased the risk of being SGA, while a higher BMI and weight gain during pregnancy decreased it ( Table 3) . Although this is based on a few subjects, Blacks were 2.14 times more likely than Caucasians to have an SGA newborn (95% CI 1.28 to 3.56) ( Table 3 ).
Stratification on AD DosageDuring Pregnancy
The associations described above prompted an investigation on the characteristics of women receiving other ADs, compared with patients receiving SSRIs. This was deemed important because other ADs are generally prescribed to patients that do not respond to SSRI or tricyclic ADs. 25 • 26 As shown in Table 4 , subjects who were prescribed other ADs seemed to have more severe psychopathologies.
Among the other ADs group, venlafaxine was the most frequent type of AD prescribed during the second trimester of pregnancy (73.9% of all other ADs). We therefore stratified the models on dose ofvenlafaxine received during the second trimester. This was done to determine whether the association observed was due to venlafaxine or rather to severity of the underlying psychopathology.
Low-dose venlafaxine use during the second trimester, defined as 150 mg/day or less, was statistically associated with an infant born SGA (ARR = 2.98; 95% CI 1.60 to 7.70) ( Table 5 ). The dosage range for venlafaxine users in the low-dose category was between 73 mg/dayand 146 mg/day. High-dose venlafaxine use during the second trimester, defined as greater than 150 mg!day, was not statistically associated with an infant born SGA (ARR = lAO; 95% CI 0.18 to 10.61) ( Table 5 ).
Discussion
Unlike previous studies that focused on the risk of prematurity and LBW associated with AD exposure during pregnancy, our study is one of the few whose primary objective was to investigate the effect of gestational exposure to ADs on the risk ofinfants born SGA. A potential association was found between other ADs used during the second trimester of pregnancy and the risk of infants born SGA. Co-exposure to different AD classes during the second trimester may also significantly increase the risk of infants born SGA. Despite its large point estimate, the association with SSRIs was not statistically significant during the second trimester of pregnancy, and warrants further investigation in larger populations exposed to SSRIs during pregnancy. As expected, tobacco use, hypertension, race, and markers ofdisease severity (having at least one mental disorder diagnosis during pregnancy) were risk factors for having an infant born SGA?7, 28 Conversely, BMI and weight gain during pregnancy decreased the risk of having an infant born SGA.
Confounding
Confounding by indication is a common problem in pharmacoepidemiologic studies. This happens when factors associated with the choice of therapy are risk factors for the study outcome. Although a randomized clinical trial can eliminate such confounding, it would not be an ethical design to use when investigating outcomes such as SGA. The wealth of data recorded in the prospective recordings of the administrative databases of the province of Quebec allowed us to adjust for many factors associated with the risk of SGA and with the selection of AD treatment. However, as in all observational studies, there is the possibility of residual confounding. Most notably, severity ofdisease or treatment nonresponsiveness, 2 strong determinants of SGA could only be accounted for 648 indirectly by using proxies such as AD dosage received. When we stratified our analyses on dosages of venlafaxine received, we observed a strong association with infants born SGA among women who received dosages of 150 mg/day or less. However, the association was lost among women who received dosages of greater than 150 mg/day, although the relative risks remained comparatively high. Thus it appears that women who received dosages above 150 mg/day may have had a better control of their psychiatric condition, whereas those who received dosages less than 150 mg/day had a poorer control of their psychiatric condition. If that were the case, it would be the underlying psychiatric condition and not the AD used that would be responsible for the observed increased risk for infants born SGA associated with the other ADs class.i" However, accurate interpretation is limited because stratification on dosages resulted in strata in few subjects. As a result, the absence of an association among women who received dosages greater than 150 mg/day may be due to a lack ofstatistical power and a lack of stable estimates. Studies with larger sample sizes are needed to confirm or refute this hypothesis.
The association found between other ADs and infants born SGA was only present during the second trimester. The .. La Revue canadienne de psychiatrie, vol 55, no10, octobre 2010 second trimester is a time when the fetal nutrition is essentially mediated through the placental blood." SSRIs and other ADs are known to induce vasoconstrictions through the modulation ofserotonin. 31 Stress and anxiety have also been shown to induce the same effect. In theory, both ADs and psychiatric conditions can cause blood vessel vasoconstrictions, thereby reducing the blood flow to the fetus, providing a possible mechanism for infants born SGA. However, more research is needed to determine the exact independent contributory role of ADs and psychiatric conditions in their relation to infants born SGA.
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Strengths and Limitations
A major strength ofour study was the large study population and the accuracy of the information on medications dispensed throughout pregnancy. The administrative databases used give full details on the names, dosages, quantities, and treatment duration of medications dispensed. Because these databases provide information on medications dispensed, they do not reflect actual intake ofthese agents. However, our study has the advantage over field studies, which usually rely on self-reported drug histories, and therefore, prone to recall bias. Moreover, De long van den Berg et ae 2 found that most filled prescriptions by pregnant women are taken. 
